Session Information
-
WCLC 2021
2022 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
P40 - Multimodality of Advanced Lung Cancer - Clinical Outcomes
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Multimodality of Advanced Lung Cancer
-
+
P40.01 - Maintenance Anlotinib After Induction Therapy With Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Phase 2 Study
00:00 - 00:00 | Presenter: Yongqian Shu
- Abstract
Loading... -
+
P40.02 - Pemetrexed in Advanced-stage Lymphoepithelioma Carcinoma of Lung
00:00 - 00:00 | Presenter: Ri-Qiang Liao
- Abstract
Loading... -
+
P40.03 - Palliative Radiotherapy Decreased Circulating White Blood Cells in Patients With Stage IV Lung Cancer
00:00 - 00:00 | Presenter: Feng Ming Spring Kong
- Abstract
Loading... -
+
P40.04 - CNS Adverse Events and Survival in Patients with NSCLC Brain Metastases Treated With Concurrent Radiation and Immunotherapy
00:00 - 00:00 | Presenter: David Riley
- Abstract
Loading... -
+
P40.05 - Radiation-Related Platelet Reduction in Patients With Stage IV Lung Cancer
00:00 - 00:00 | Presenter: Feng Ming Spring Kong
- Abstract
Loading... -
+
P40.06 - A Real-World Study: Efficacy and Safety of Anlotinib for Advanced Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Qian Chu
- Abstract
Loading... -
+
P40.07 - Immunotherapy Toxicity in Lung Cancer & the Impact of Thoracic Radiation Therapy
00:00 - 00:00 | Presenter: Ciani Ellison
- Abstract
Loading... -
+
P40.08 - Bone-Targeted Agents Improve Survival in High Bone Tumor Burden Advanced Non-Small-Cell-Lung Cancer Patients Treated With PD-(L)1 Inhibitors
00:00 - 00:00 | Presenter: Sara Manglaviti
- Abstract
Loading... -
+
P40.09 - Using Real World Data to Identify a Patient Cohort Who Require Prehabilitation to Improve Treatment Rates for Stage 3 NSCLC
00:00 - 00:00 | Presenter: Benjamin W. A. Langley
- Abstract
Loading... -
+
P40.10 - Brain Metastases in Patients With Non-Small Cell Lung Cancer Treated With Immunotherapy. Real World Data From a Tertiary Hospital in Spain
00:00 - 00:00 | Presenter: Yago Garitaonaindia
- Abstract
Loading... -
+
P40.11 - Trimodality Therapy Protocol in 144 Superior Sulcus Patients: Good Results Even for Extended Resections and Indications
00:00 - 00:00 | Presenter: Marinus Anne Paul
- Abstract
Loading... -
+
P40.12 - Cardiotoxicity in Lung Cancer Patients Treated With Immune-Checkpoints Inhibitors
00:00 - 00:00 | Presenter: Mariola Blanco Clemente
- Abstract
Loading... -
+
P40.13 - Lung Cancer 5-Year Survival in Croatia - Our Experience
00:00 - 00:00 | Presenter: Marko Jakopović
- Abstract
Loading... -
+
P40.14 - Efficacy and Safety of Endostar Combined With Camrelizumab and Chemotherapy in Treatment of Advanced NSCLC: A Multi-Center Retrospective Study
00:00 - 00:00 | Presenter: Lin Wu
- Abstract
Loading... -
+
P40.15 - Proton Pump Inhibitors, Prior Therapy and Survival in Patients Treated With Immune Checkpoint Inhibitors for Advanced NSCLC
00:00 - 00:00 | Presenter: Marium Husain
- Abstract
Loading... -
+
P40.16 - Real-World Data and Racial Outcomes for NSCLC in The Chemo-Immunotherapy Era
00:00 - 00:00 | Presenter: Danny Markabawi
- Abstract
Loading... -
+
P40.17 - Palliative Radiotherapy Decreased K+ and Ca2+of the Blood in Patients With Stage IV Lung Cancer
00:00 - 00:00 | Presenter: Feng Ming Spring Kong
- Abstract
Loading... -
+
P40.18 - Second Line Immunotherapy After Progression on a Different First Line Immunotherapy in Advanced Non-Small Cell Lung Cancer With Focus On Elderly
00:00 - 00:00 | Presenter: Karan Seegobin
- Abstract
Loading... -
+
P40.19 - Efficacy and Toxicity of Third-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Sara Manglaviti
- Abstract
Loading... -
+
P40.20 - Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients With Metastatic Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Sabin Goktas Aydin
- Abstract
Loading...
-
+
P41 - Multimodality of Advanced Lung Cancer - Clinical Trials, Case Report
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Multimodality of Advanced Lung Cancer
-
+
P41.01 - Abscopal Response Induced by Thermal Ablation in Advanced NSCLC Patients Failed From Immunotherapy: Preliminary Result From a Phase 2 Trial
00:00 - 00:00 | Presenter: Chuchu Shao
- Abstract
Loading... -
+
P41.02 - Surgery for Small Pulmonary NUT Carcinoma: Case Report
00:00 - 00:00 | Presenter: YUICHI SAITO
- Abstract
Loading...
-
+
P42 - Multimodality of Advanced Lung Cancer - Prognostic Factors
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Multimodality of Advanced Lung Cancer
-
+
P42.01 - Tumor Size is an Independent Prognostic Factor after Pulmonary Metastasectomy
00:00 - 00:00 | Presenter: Simona Sobrero
- Abstract
Loading... -
+
P42.02 - Prognostic Indicators for Conventional Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients in Resource-Limited Country
00:00 - 00:00 | Presenter: Chawalit Chayangsu
- Abstract
Loading... -
+
P42.03 - Predictive Factors of Response to PD-(L)1 Inhibitors in Patients With Advanced Non-Small Cell Lung and High PD-L1 Expression
00:00 - 00:00 | Presenter: Andrés Barba Joaquín
- Abstract
Loading... -
+
P42.04 - Prognosis Factors in Advanced Lung Cancer Patients Treated With Checkpoint Inhibitor-Based Immunotherapy
00:00 - 00:00 | Presenter: Kan Wu
- Abstract
Loading...
-
+
P43 - Multimodality of Advanced Lung Cancer - Others
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Multimodality of Advanced Lung Cancer
-
+
P43.01 - Three-Dimensional Virtual Planning for Nodule Resection in Solid Organs: A Systematic Review and Meta-Analysis
00:00 - 00:00 | Presenter: Paulo Alfredo Casanova Schulze
- Abstract
Loading... -
+
P43.02 - Inconsistencies Within Biomarker Test Reports Provide Opportunities for Future Patient Education
00:00 - 00:00 | Presenter: Nikki Martin
- Abstract
Loading... -
+
P43.03 - LUPA-01: An Observational Study to Monitor Lung Cancer Patients’ Activity and Assess Performance Status through a Wearable Device in Spain
00:00 - 00:00 | Presenter: Santiago Ponce Aix
- Abstract
Loading...
-
+
P44 - Nursing and Allied Health Professionals
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Nursing and Allied Health Professionals
-
+
P44.01 - Clinical Predictive Markers of Response to Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC).
00:00 - 00:00 | Presenter: Raena Denise Rhone
- Abstract
Loading... -
+
P44.02 - Prevalence, Onset, and Severity of Renal Impairment With Pemetrexed/Carboplatin +/- Pembrolizumab in Metastatic Non-Squamous NSCLC
00:00 - 00:00 | Presenter: Jennifer Z Miller
- Abstract
Loading...
-
+
P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P45.01 - Therapeutic effectiveness of Lorlatinib After Alectinib in Japanese Patients With ALK-Positive NSCLC in Real-World
00:00 - 00:00 | Presenter: Yasushi Goto
- Abstract
Loading... -
+
P45.02 - Molecular Profile of Resistance Mutations Post Multiple Lines of Tyrosine Kinase Inhibitors in ALK-Positive Non-Small-Cell Lung Cancer
00:00 - 00:00 | Presenter: Moushumi Suryavanshi
- Abstract
Loading... -
+
P45.03 - Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy
00:00 - 00:00 | Presenter: Enriqueta Felip
- Abstract
Loading... -
+
P45.04 - Phase II Study of Brigatinib in ROS1 Positive Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated with Crizotinib: Barossa Cohort 2
00:00 - 00:00 | Presenter: Jun Sakakibara-Konishi
- Abstract
Loading... -
+
P45.05 - Sequencing of PD-1 Inhibitors and TKIs in Metastatic NSCLC with MET Exon 14 Skipping Mutation May Influence Survival
00:00 - 00:00 | Presenter: Sally CM Lau
- Abstract
Loading... -
+
P45.06 - Overall Survival From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1+ Advanced Non-Small-Cell Lung Cancer
00:00 - 00:00 | Presenter: Yi-Long Wu
- Abstract
Loading... -
+
P45.07 - Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK+ NSCLC
00:00 - 00:00 | Presenter: Sabine Schmid
- Abstract
Loading... -
+
P45.08 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading... -
+
P45.09 - Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada
00:00 - 00:00 | Presenter: Simren Chotai
- Abstract
Loading... -
+
P45.10 - Effects of ALK Tyrosine Kinase Inhibitors in the Treatment of Metastatic NSCLC: A Systematic Review and Meta-Analysis
00:00 - 00:00 | Presenter: Michela Febbraro
- Abstract
Loading... -
+
P45.11 - Co-occurring CDKN2A/B Alteration Is Associated With Worse Survival Outcomes in Advanced ALK-Positive Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Oscar Arrieta
- Abstract
Loading... -
+
P45.12 - Renal Function Change During Alectinib in ALK Rearranged Non-Small Cell Lung Cancer: A Retrospective Multicentre Analysis
00:00 - 00:00 | Presenter: Chiara Paratore
- Abstract
Loading... -
+
P45.13 - Efficacy and Safety of Crizotinib in Real-World ROS1-rearranged NSCLC: A Retrospective Canadian Cohort
00:00 - 00:00
- Abstract
Loading... -
+
P45.14 - Real-World Experience on Treatment of crizotinib in ALK/ROS1/MET Alterated Non-Small-Cell Lung Cancer Patients in China
00:00 - 00:00 | Presenter: Shaoyu Yang
- Abstract
Loading... -
+
P45.15 - Clinical Outcomes, Long-Term Survival and Toleration With Sequential Therapy of First-Line Crizotinib Followed by Alectinib in ALK+ NSCLC
00:00 - 00:00 | Presenter: Zihua Zou
- Abstract
Loading... -
+
P45.16 - Adverse Event Burden of Oral Tyrosine Kinase Inhibitors in EGFR and ALK Metastatic Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: David Riley
- Abstract
Loading... -
+
P45.17 - Outcomes of Patients on ALK Inhibitor Therapy in NHS Tayside Scotland UK
00:00 - 00:00 | Presenter: Sherie George
- Abstract
Loading... -
+
P45.18 - NSCLC Patients With ALK Gene Rearrangement – Croatian Experience
00:00 - 00:00 | Presenter: Marko Jakopović
- Abstract
Loading...
-
+
P46 - Novel Therapeutics and Targeted Therapies - Case Report
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P46.01 - Progression After Targeted-therapy – An EGFR Case Report
00:00 - 00:00 | Presenter: Francisco Neri
- Abstract
Loading... -
+
P46.02 - Impact of Real-World DNA- and RNA-Based Rebiopsy Testing in EGFR-Mutated NSCLC Progressing on Osimertinib.
00:00 - 00:00 | Presenter: Edyta Maria Urbanska
- Abstract
Loading... -
+
P46.03 - Targeting ROS1 Gene Rearrangement by Crizotinib as Neoadjuvant Treatment Before Definitive Radiotherapy in Locally Advanced NSCLC
00:00 - 00:00 | Presenter: Jens Benn Sørensen
- Abstract
Loading... -
+
P46.04 - Different Effects of Crizotinib Treatment in Three Lung Adenocarcinoma Patients With Various ROS1 Fusion Variants
00:00 - 00:00 | Presenter: Yuta Ohishi
- Abstract
Loading... -
+
P46.05 - Durable Response to Double Dose Osimertinib 160mg in EGFR-Mutated Non-Small Cell Lung Cancer With Brain Metastases
00:00 - 00:00 | Presenter: Myungwoo Nam
- Abstract
Loading... -
+
P46.06 - Response of an Advanced Lung Cancer Mass to Targeted Therapy
00:00 - 00:00 | Presenter: Paulo Alfredo Casanova Schulze
- Abstract
Loading... -
+
P46.07 - Afatinib-Related Pneumonitis in Metastatic EGFR-Positive NSCLC
00:00 - 00:00 | Presenter: Sita Andarini
- Abstract
Loading...
-
+
P47 - Novel Therapeutics and Targeted Therapies - Clinical Trial in Progress
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P47.01 - SGNTUC-019: Phase 2 Study of Tucatinib and Trastuzumab in Solid Tumors: Lung Cancer Cohorts (Clinical Trial in Progress)
00:00 - 00:00 | Presenter: Martin Reck
- Abstract
Loading... -
+
P47.02 - EV-202: Phase 2 Study of Enfortumab Vedotin for Previously Treated Advanced Solid Tumors Including Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Seema Gorla
- Abstract
Loading... -
+
P47.03 - Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer: Stage 2
00:00 - 00:00 | Presenter: Jonathan Goldman
- Abstract
Loading... -
+
P47.04 - TROPION-Lung02: Datopotamab Deruxtecan (Dato-DXd) Plus Pembrolizumab and Platinum-Based Chemotherapy in Advanced NSCLC
00:00 - 00:00 | Presenter: Benjamin Levy
- Abstract
Loading... -
+
P47.05 - A Phase 2 Study of Datopotamab Deruxtecan (Dato-DXd) in Advanced NSCLC With Actionable Genomic Alterations (TROPION-Lung05)
00:00 - 00:00 | Presenter: Melissa L Johnson
- Abstract
Loading... -
+
P47.06 - TROPION-Lung04: Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab and Platinum-Based Chemotherapy in Advanced NSCLC
00:00 - 00:00 | Presenter: Hossein Borghaei
- Abstract
Loading... -
+
P47.07 - KEAPSAKE Study of Telaglenastat vs Placebo Plus Standard-of-Care in 1L KEAP1/NRF2-Mutated Non-Squamous Metastatic NSCLC
00:00 - 00:00 | Presenter: David R. Spigel
- Abstract
Loading... -
+
P47.08 - A Phase II, Single-arm, Multicenter, Efficacy of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC
00:00 - 00:00 | Presenter: Sehhoon Park
- Abstract
Loading... -
+
P47.09 - Tepotinib + Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
00:00 - 00:00 | Presenter: Christophe Dooms
- Abstract
Loading... -
+
P47.10 - Neoadjuvant Osimertinib in EGFR-Mutant Stage IIIA/B NSCLC - A Phase 2 Open-Label Pilot Study
00:00 - 00:00 | Presenter: Waleed Kian
- Abstract
Loading... -
+
P47.11 - COMPEL: Chemotherapy With/Without Osimertinib in Patients With EGFRm Advanced NSCLC and Progression on First-Line Osimertinib
00:00 - 00:00 | Presenter: Lecia V. Sequist
- Abstract
Loading... -
+
P47.12 - ALKternate: A Proof of Concept Study in ALK-Rearranged NSCLC Alternating Lorlatinib With Crizotinib After Disease Progression
00:00 - 00:00 | Presenter: Malinda Itchins
- Abstract
Loading... -
+
P47.13 - First-in-Human, Dose Escalation and Expansion Study of MT-6402 in Patients With PD-L1 Expressing Advanced Solid Tumors
00:00 - 00:00 | Presenter: David R. Spigel
- Abstract
Loading... -
+
P47.14 - Study Design of SCORPION: Multi-Center, Phase II Study Following Platinum-Based Chemotherapy Plus ICIs in Patients with NSCLC
00:00 - 00:00 | Presenter: Reiko Matsuzawa
- Abstract
Loading... -
+
P47.15 - A Phase IA Study of Ceritinib + Trametinib in Patients With Advanced ALK- or ROS1- Rearranged NSCLC: Preliminary Results
00:00 - 00:00 | Presenter: Matthew Lara
- Abstract
Loading... -
+
P47.16 - Preliminary Efficacy and Safety Results About a Phase II Trial of Afatinib and Bevacizumab in Untreated NSCLC Harboring EGFR Sensitive Mutations
00:00 - 00:00 | Presenter: Yu Feng
- Abstract
Loading... -
+
P47.17 - Capmatinib vs Docetaxel in Pretreated Patients With MET Exon 14 Skipping–mutated Stage IIIB/IIIC or IV NSCLC (GeoMETry-III)
00:00 - 00:00 | Presenter: Pierre-Jean Souquet
- Abstract
Loading... -
+
P47.18 - Almonertinib With Radiotherapy vs Concurrent Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC (ADVANCE Trial)
00:00 - 00:00 | Presenter: Nan Bi
- Abstract
Loading...
-
+
P48 - Novel Therapeutics and Targeted Therapies - EGFR
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P48.01 - Anlotinib Plus Docetaxel vs Docetaxel for 2nd-Line Treatment of EGFR negative NSCLC (ALTER-L018): A Randomized Phase II Trial
00:00 - 00:00 | Presenter: Lin Wu
- Abstract
Loading... -
+
P48.02 - Real-World Data of Dacomitinib in EGFR TKI-Naïve Patients With Advanced Epidermal Growth Factor Receptor-positive Non-small Cell Lung Cancer
00:00 - 00:00 | Presenter: Jinyao Zhang
- Abstract
Loading... -
+
P48.03 - Spectrum of Resistance Mechanisms to First, Second and Third Generation Tyrosine Kinase Inhibitors in EGFR Mutant NSCLC Patients
00:00 - 00:00 | Presenter: Moushumi Suryavanshi
- Abstract
Loading... -
+
P48.04 - EGFR Germline Mutations in Chinese Lung Cancer Patients: A Single Institutional, Retrospective Study
00:00 - 00:00 | Presenter: Chengzhi Zhou
- Abstract
Loading... -
+
P48.05 - Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?
00:00 - 00:00 | Presenter: Miguel Garcia
- Abstract
Loading... -
+
P48.06 - A Network Meta-Analysis (MA) of First-Line Lung Cancer Treatment With Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)
00:00 - 00:00 | Presenter: Yvonne Ang
- Abstract
Loading... -
+
P48.07 - Real-World Impact of Upfront Osimertinib in Reducing Health Resource Utilization by Preventing Brain Metastases
00:00 - 00:00 | Presenter: Francesca Simionato
- Abstract
Loading... -
+
P48.08 - The Efficacy and Clinical Survival Outcome of Different First-Line Treatments in EGFR Mutant Non-Small Cell Lung Cancer With Brain Metastases
00:00 - 00:00 | Presenter: Huijuan wang
- Abstract
Loading... -
+
P48.09 - Body Mass Index Predicts Benefit From Adding Metformin to EGFR-TKIs in Patients With Lung Adenocarcinoma: Subanalysis From an RCT
00:00 - 00:00 | Presenter: Oscar Arrieta
- Abstract
Loading... -
+
P48.10 - Efficacy of EGFR-TKIs vs TKIs Plus Chemotherapy as First-Line Treatment in EGFR-Mutation Lung Adenocarcinoma With Liver Metastases
00:00 - 00:00 | Presenter: Huijuan wang
- Abstract
Loading... -
+
P48.11 - ctDNA Dynamic Detection Reveals the Advantages of EGFR Tyrosine Kinase Inhibitors Combined With Chemotherapy in NSCLC Patients
00:00 - 00:00 | Presenter: Weineng Feng
- Abstract
Loading... -
+
P48.12 - Concurrent Chemotherapy and First-Generation EGFR-TKI as First-Line Treatment in Advanced Lung Adenocarcinoma Harboring EGFR Mutation
00:00 - 00:00 | Presenter: Ziyi Xu
- Abstract
Loading... -
+
P48.13 - Clinical Factors Associated With Treatment Outcomes in EGFR Mutant Non-Small Cell Lung Cancer Patients. Real Life Experience in Argentina
00:00 - 00:00 | Presenter: luis Roberto basbus
- Abstract
Loading... -
+
P48.14 - Metastatic NSCLC -Re-Challenging With Fist Generation TKI After a Drug Free Holiday After Resistance to 3rd Generation TKI
00:00 - 00:00 | Presenter: Suryakanta Acharya
- Abstract
Loading... -
+
P48.15 - EGFR Mutated Non-Small Cell Lung Cancer Treatment Pathway – What Is the Best Way?
00:00 - 00:00 | Presenter: Marta Soares
- Abstract
Loading... -
+
P48.16 - The Effect and Safety of Anlotinib as a Third Line or Further Therapy in Non-Small Cell Lung Cancer Patients With Liver Metastasis
00:00 - 00:00 | Presenter: Yinchen Shen
- Abstract
Loading... -
+
P48.17 - Real-World Study of Patients With EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Treated With First-Line Osimertinib
00:00 - 00:00 | Presenter: Jorge Nieva
- Abstract
Loading...
-
+
P49 - Novel Therapeutics and Targeted Therapies - EGFR Major
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P49.01 - Drug Holiday Based on Minimal Residual Disease Status After Local Therapy Following EGFR-TKI Treatment for Patients With Advanced NSCLC
00:00 - 00:00 | Presenter: Song Dong
- Abstract
Loading...
first
prev
